{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:08:46Z","timestamp":1761491326993,"version":"3.37.3"},"reference-count":49,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T00:00:00Z","timestamp":1639785600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Virology"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study aimed to assess the efficacy and safety of different medications available at present for severe coronavirus disease 2019 (COVID\u201019) infection. We searched databases for randomized controlled trials (RCTs) published up to April 30, 2021, with Chinese or English language restriction, of medications recommended for patients (aged 18 years or older) with severe COVID\u201019 infection. We extracted data on trials and patient characteristics, and the following primary outcomes: all\u2010cause mortality (ACM), and treatment\u2010emergent adverse events (TEAEs). We identified 1855 abstracts and of these included 15 RCTs comprising 3073 participants through database searches and other sources. In terms of efficacy, compared with the standard of care (SOC) group, no significant decrease in ACM was found in \u03b1\u2010lipoic acid, convalescent plasma (CP), azithromycin, tocilizumab, methylprednisolone, interferon beta, CP\/SOC, high dosage sarilumab, low dosage sarilumab, remdesivir, lopinavir\u2013ritonavir, auxora, and placebo group. Compared with placebo, we found that a significant decrease in ACM was only found in methylprednisolone (odds ratio [OR]: 0.16, 95% confidence interval [CI]: 0.03\u20130.75]. With respect to TEAEs, the CP group showed lower TEAEs than placebo (OR: 0.07, 95% CI: 0.01\u20130.58) or SOC (OR: 0.05, 95% CI: 0.01\u20130.42) group for the therapy of severe COVID\u201019 patients. This study only demonstrated that methylprednisolone was superior to placebo in treating patients with severe COVID\u201019 infection. Meanwhile, this further confirmed that the safety of other treatment interventions might be inferior to CP for the therapy of severe COVID\u201019 patients.<\/jats:p>","DOI":"10.1002\/jmv.27512","type":"journal-article","created":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T08:51:01Z","timestamp":1639039861000},"page":"1617-1626","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and safety of current treatment interventions for patients with severe COVID\u201019 infection: A network meta\u2010analysis of randomized controlled trials"],"prefix":"10.1002","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2899-7626","authenticated-orcid":false,"given":"Qinglin","family":"Cheng","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases Hangzhou Center for Disease Control and Prevention Hangzhou Zhejiang China"},{"name":"Department of Epidemiology and Health Statistics, School of Medicine Hangzhou Normal University Hangzhou Zhejiang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5564-911X","authenticated-orcid":false,"given":"Gang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases Hangzhou Center for Disease Control and Prevention Hangzhou Zhejiang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junfang","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases Hangzhou Center for Disease Control and Prevention Hangzhou Zhejiang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingjun","family":"Jia","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases Hangzhou Center for Disease Control and Prevention Hangzhou Zhejiang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zijian","family":"Fang","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases Hangzhou Center for Disease Control and Prevention Hangzhou Zhejiang China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,12,18]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.05.001"},{"key":"e_1_2_11_3_1","unstructured":"World Health Organization. WHO coronavirus (COVID\u201019) dashboard. Geneva: WHO;\u00a02020. Accessed May 7 2021.https:\/\/covid19.who.int\/"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2023184"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-89444-5"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2033130"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-20-0481"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.4274\/tjps.galenos.2020.88864"},{"key":"e_1_2_11_9_1","article-title":"Efficacy and safety of remdesivir in hospitalized Covid\u201019 patients: systematic review and meta\u2010analysis including network meta\u2010analysis [published online ahead of print, 2020 Oct 31]","volume":"31","author":"Elsawah HK","year":"2020","journal-title":"Rev Med Virol"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106222"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14466"},{"key":"e_1_2_11_12_1","unstructured":"World Health Organization (WHO). Laboratory testing for coronavirus disease (\u200eCOVID\u201019)\u200e in suspected human cases: interim guidance 19 March 2020. Accessed April 3 2021.https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/331501\/WHO-COVID-19-laboratory-2020.5-eng.pdf"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/TA.0b013e31827013e9"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.20-0873"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-017-0473-z"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-016-1583-7"},{"issue":"9","key":"e_1_2_11_18_1","first-page":"1","article-title":"Convalescent plasma for COVID\u201019: a multicenter, randomized clinical trial","volume":"2","author":"Avenda\u00f1o\u2010Sol\u00e0 C","year":"2020","journal-title":"medRxiv"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001282"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01061-20"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02808-2020"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31862-6"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00099-0"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.10044"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-03220-x"},{"key":"e_1_2_11_26_1","article-title":"Remdesivir for severe COVID\u201019 versus a cohort receiving standard of care [published online ahead of print, 2020 Jul 24]","author":"Olender SA","year":"2020","journal-title":"Clin Infect Dis"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106903"},{"issue":"3","key":"e_1_2_11_28_1","first-page":"357","article-title":"The therapeutic potential of convalescent plasma therapy on treating critically\u2010ill COVID\u201019 patients residing in respiratory care units in hospitals in Baghdad, Iraq","volume":"28","author":"Rasheed AM","year":"2020","journal-title":"Infez Med"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2031304"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n84"},{"key":"e_1_2_11_31_1","first-page":"1","article-title":"A randomized, single\u2010blind, group sequential, active\u2010controlled study to evaluate the clinical efficacy and safety of \u03b1\u2010Lipoic acid for critically ill patients with coronavirus disease 2019 (COVID\u201019)","author":"Zhong M","year":"2020","journal-title":"medRxiv"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104872"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.18632\/aging.203522"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.200642"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-015-4095-4"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.0994"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0248132"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI150646"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1037\/a0023951"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-021-00423-9"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.729559"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000001672"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m2980"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12926"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.660688"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.06.107"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2020.06.028"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI140200"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc6027"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2021.1847269"}],"container-title":["Journal of Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.27512","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jmv.27512","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.27512","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T02:38:20Z","timestamp":1693103900000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmv.27512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,18]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1002\/jmv.27512"],"URL":"https:\/\/doi.org\/10.1002\/jmv.27512","archive":["Portico"],"relation":{},"ISSN":["0146-6615","1096-9071"],"issn-type":[{"type":"print","value":"0146-6615"},{"type":"electronic","value":"1096-9071"}],"subject":[],"published":{"date-parts":[[2021,12,18]]},"assertion":[{"value":"2021-06-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}